MX2023000151A - Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis. - Google Patents
Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis.Info
- Publication number
- MX2023000151A MX2023000151A MX2023000151A MX2023000151A MX2023000151A MX 2023000151 A MX2023000151 A MX 2023000151A MX 2023000151 A MX2023000151 A MX 2023000151A MX 2023000151 A MX2023000151 A MX 2023000151A MX 2023000151 A MX2023000151 A MX 2023000151A
- Authority
- MX
- Mexico
- Prior art keywords
- mometasone
- verapamil
- therapy
- treatment
- combination
- Prior art date
Links
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 title abstract 2
- 229960001664 mometasone Drugs 0.000 title abstract 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 title 1
- 229940092418 combination verapamil Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 201000009890 sinusitis Diseases 0.000 abstract 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001722 verapamil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Described herein are methods for treating rhinosinusitis by administering to the subject an effective amount of verapamil and mometasone as well as compositions and kits for treating rhinosinusitis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041953P | 2020-06-21 | 2020-06-21 | |
| PCT/US2021/038281 WO2021262608A1 (en) | 2020-06-21 | 2021-06-21 | Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000151A true MX2023000151A (en) | 2023-02-16 |
Family
ID=79281745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000151A MX2023000151A (en) | 2020-06-21 | 2021-06-21 | Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230226008A1 (en) |
| EP (1) | EP4167988A4 (en) |
| JP (1) | JP2023531655A (en) |
| KR (1) | KR20230026460A (en) |
| CN (1) | CN116209449A (en) |
| AU (1) | AU2021297174A1 (en) |
| BR (1) | BR112022026070A2 (en) |
| CA (1) | CA3187584A1 (en) |
| IL (1) | IL299210A (en) |
| MX (1) | MX2023000151A (en) |
| WO (1) | WO2021262608A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2533846C (en) * | 2003-07-29 | 2012-08-28 | Universitaetsklinikum Muenster | Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| ES2340777T3 (en) * | 2004-01-21 | 2010-06-09 | Schering Corporation | METHOD OF TREATMENT OF ACUTE RHINOSINUSITIS. |
| US20110020457A1 (en) * | 2006-08-14 | 2011-01-27 | Wayne State University | Polymer-surfactant nanoparticles for sustained release of compounds |
| EP2938339B1 (en) * | 2012-12-27 | 2020-08-19 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with p-glycoprotein inhibitors |
-
2021
- 2021-06-21 BR BR112022026070A patent/BR112022026070A2/en unknown
- 2021-06-21 CA CA3187584A patent/CA3187584A1/en active Pending
- 2021-06-21 AU AU2021297174A patent/AU2021297174A1/en active Pending
- 2021-06-21 US US18/011,637 patent/US20230226008A1/en active Pending
- 2021-06-21 JP JP2022578808A patent/JP2023531655A/en active Pending
- 2021-06-21 CN CN202180051224.3A patent/CN116209449A/en active Pending
- 2021-06-21 IL IL299210A patent/IL299210A/en unknown
- 2021-06-21 EP EP21827979.2A patent/EP4167988A4/en active Pending
- 2021-06-21 KR KR1020237002105A patent/KR20230026460A/en active Search and Examination
- 2021-06-21 MX MX2023000151A patent/MX2023000151A/en unknown
- 2021-06-21 WO PCT/US2021/038281 patent/WO2021262608A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3187584A1 (en) | 2021-12-30 |
| WO2021262608A1 (en) | 2021-12-30 |
| KR20230026460A (en) | 2023-02-24 |
| IL299210A (en) | 2023-02-01 |
| US20230226008A1 (en) | 2023-07-20 |
| JP2023531655A (en) | 2023-07-25 |
| BR112022026070A2 (en) | 2023-01-17 |
| EP4167988A4 (en) | 2024-07-03 |
| CN116209449A (en) | 2023-06-02 |
| AU2021297174A1 (en) | 2023-02-02 |
| EP4167988A1 (en) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008777A (en) | Microbiome related immunotherapies. | |
| EA202190630A1 (en) | COMBINED THERAPY METHODS | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| EA201890146A1 (en) | METHODS OF TREATMENT OF SOLID TUMORS USING COMBINED THERAPY BY mTOR INHIBITOR IN THE FORM OF NANOPARTICLES | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA202192122A1 (en) | COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION | |
| MX2021008610A (en) | Cancer treatment using combinations of erk and raf inhibitors. | |
| EA201650134A1 (en) | SPECIFIC COMBINED THERAPY OF MALIGNANT TUMORS BY CYTOSTATIC AND ITS MODIFIER | |
| CR20220207A (en) | Therapeutic compounds and methods of use | |
| MX2023004156A (en) | Combination therapy for treating cancer. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2021006156A (en) | Compounds useful in hiv therapy. | |
| JOP20200244A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| EA202193111A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
| MX2021007330A (en) | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor. | |
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| MX2019002047A (en) | Methods and compositions for treating cutaneous fungal infections. | |
| PH12021550832A1 (en) | Combination of small molecule cd-47 inhibitors with other anti-cancer agents | |
| MX2019004804A (en) | Treatment of prurigo nodularis. | |
| MX2022005250A (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies. | |
| MX2023000151A (en) | Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis. | |
| MX2023006704A (en) | Dsg2 compositions and methods for the treatment of covid-19. | |
| MX2023004881A (en) | Pde9 inhibitors for treating cardiac failure. | |
| MX2022016179A (en) | Compounds and methods for treating fungal infections. | |
| MX2022008632A (en) | Ccr5 binding agent for treatment of ccr5 positive metastatic cancer. |